收藏切换
Cost-effectiveness threshold considerations in innovative drug access
收藏切换
Jinyan TANG, Ruixin WANG, xuanxuan YAN, Yiqing WANG, Xiaohua YING*
World Clinical Drug | 2022, 43(10) : 1269 - 1276
Less
收藏切换
World Clinical Drug | 2022, 43(10): 1269-1276
• Topic •
Cost-effectiveness threshold considerations in innovative drug access
Full
Jinyan TANG, Ruixin WANG, xuanxuan YAN, Yiqing WANG, Xiaohua YING*
Affiliations
  • School of Public Health, Fudan University, Shanghai 200032, China
Published: 2022-10-10 doi: 10.13683/j.wph.2022.10.007
Outline
收藏切换

Cost-effectiveness threshold (CET) can judge the economy efficiency of different medical intervention measures. It is an important reference standard for medical insurance directory access. It is also an important pharmacoeconomic evidence for the lack of medical insurance access negotiations for innovative drugs in China. This paper summarizes the experience of the application of CET in the world and lays a foundation for the determination and application of innovative drug CET in China. CET is an important basis for the selection of health interventions in many countries. It is mainly divided into implicit threshold and explicit threshold, most countries use implicit threshold for decision-making. The per capita GDP multiple is the CET mode selected by most countries. In the face of different application scenarios of innovative drugs, such as rare diseases treatment, end-stage treatment and disease treatment of different severity, countries make adjustments to different degrees on the basis of general CET. It is not clear whether CET is used in China's health decision-making. It is suggested to explore the threshold and level in line with China's national conditions on the basis of international experience, focus on exploring the application of hidden threshold in medical insurance access and preferential policies for rare diseases and end-of-life drugs and actively promote the scientific determination of CET in China.

innovative drugs  /  medical insurance access  /  cost-effectiveness threshold  /  calculation method  /  pharma-coeconomics
汤金燕, 王瑞欣, 闫萱萱, 王一清, 应晓华. 创新药物医保准入中的阈值. 世界临床药物, 2022 , 43 (10) : 1269 -1276 . DOI: 10.13683/j.wph.2022.10.007
Jinyan TANG, Ruixin WANG, xuanxuan YAN, Yiqing WANG, Xiaohua YING. Cost-effectiveness threshold considerations in innovative drug access[J]. World Clinical Drug, 2022 , 43 (10) : 1269 -1276 . DOI: 10.13683/j.wph.2022.10.007
Year 2022 volume 43 Issue 10
10
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.10.007
  • Receive Date:2022-07-20
  • Online Date:2026-11-18
  • Published:2022-10-10
Article Data
Affiliations
History
  • Received:2022-07-20
  • Revised:2022-09-20
Affiliations
    School of Public Health, Fudan University, Shanghai 200032, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.10.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT